Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986165 effect on methotrexate pharmacokinetics in healthy male volunteers
NL-OMON46408Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of deucravacitinib and methotrexate in autoimmune disease, rheumatoid arthritis (RA), psoriasis and 1 more, sponsored by Bristol Myers Squibb. Primary endpoint: Pharmacokinetics of methotrexate alone and with BMS-986165. Started Feb 2018; status: active, not recruiting.
02
Drugs
deucravacitinibmethotrexate
03
Conditions
autoimmune diseaserheumatoid arthritis (RA)psoriasisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON46408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46408.